Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409492 | 1.00 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL10367670 | 0.87 | ITGB3 (0.46) | CYP3A4CYP2C9CYP2C19ALDH1A1CASP1 | |
| SCHEMBL28688698 | 0.87 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL12606879 | 0.84 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL28677470 | 0.84 | CYP2C19 (0.56) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL7406434 | 0.83 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL7406437 | 0.83 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL7411228 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL7411226 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL24707932 | 0.80 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2025-05-15 | — | — | US | disclosed |
| US-12173021-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | UNITED THERAPEUTICS CORPORATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-11634443-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| CN-114616225-A | Treprostinil prodrugs | 联合治疗公司 | 2022-06-10 | — | — | CN | disclosed |
| US-6329373-B1 | AMIDES WITH HYDROXYAMIDES AS ENZYME INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2001-12-11 | — | — | US | disclosed |
| US-6310084-B1 | INHIBITORS OF METALLOPROTEASES INVOLVED IN TISSUE DEGRADATION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| EP-0873304-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2001-09-05 | — | — | EP | disclosed |
| US-6127427-A | ACTIVE HYDROXAMIC ACIDS INVOLVED IN TISSUE DEGRADTION AND ALSO ARE INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR FROM CELLS; RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, VISION DEFECTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-03 | — | — | US | disclosed |
| EP-0983229-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052910-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
| EP-0873304-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997019053-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154181-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | CYP3A4 138/4885CYP2C9 219/4885CYP2C19 44/4885 |
| US-20240051979-A1 | TREPROSTINIL PRODRUGS | TYMP, TK1, DCTPP1 | CYP3A4 138/4885CYP2C9 219/4885CYP2C19 44/4885 |
| US-12173021-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | CYP3A4 138/4885CYP2C9 219/4885CYP2C19 44/4885 |
| US-11634443-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | CYP3A4 138/4885CYP2C9 219/4885CYP2C19 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.